MedPath

Metabolic Syndrome and Female Breast Cancer

Completed
Conditions
Breast Cancer
Interventions
Other: Observation about the presence of metabolic syndrome
Registration Number
NCT02282592
Lead Sponsor
Catholic University of Pelotas
Brief Summary

The role among metabolic syndrome and breast cancer risk is not well understood and must be further explored. The objective of this study is to evaluate the association between metabolic syndrome and breast cancer in Southern Brazil. In this case-control study, breast cancer patients and controls without malignant disease, matched for age (±5 years) and menopausal status, were interviewed and asked to make a glucose, HDL-cholesterol and triglycerides test. Waist circumference and blood pressure were measured using standardized procedures. Metabolic Syndrome was considered by NCEP ATP III (2001) and IDF (2006) definitions. Cases and controls were compared in relation to the presence of diagnosed MetS (yes/no), number of metabolic abnormalities identified (1 to 5) for each definition, and according to each metabolic abnormality cutoff point.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
164
Inclusion Criteria
  • For cases: having newly diagnosed breast cancer without adjuvant or neoadjuvant treatment;
  • For controls: having no evidence of cancer; be matched for age and menopausal status with controls
Exclusion Criteria
  • Women with a recidivated tumor, HIV infection, renal, heart or liver disease, hypothyroidism or hyperthyroidism, mobility or neurological limitations, chronicle use of corticosteroids, pacemakers or identified with severe edema were excluded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ControlsObservation about the presence of metabolic syndromepatients without any malignant disease, matched for age an menopausal status with cases.
CasesObservation about the presence of metabolic syndromenewly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
Primary Outcome Measures
NameTimeMethod
Odds Ratio for Breast Cancer according to the presence of Metabolic Syndrome and its componentsParticipants will be evaluated only once before the first appointment with the oncologist (cases with a biopsy) and gynecologist (controls). The blood test results for Metabolic Syndrome parameters were collected in an expected average of 30 days.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath